Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$171.53 USD

171.53
9,315,157

+0.94 (0.55%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $170.89 -0.64 (-0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Centene (CNC) Tops Q3 Earnings & Revenues, Raises '17 View

by Zacks Equity Research

Centene's (CNC) strong third-quarter earnings were driven by solid revenue growth.

    Sheraz Mian headshot

    Earnings Picture Further Improves

    by Sheraz Mian

    It's not news that corporate earnings are good, but this earnings season is spotlighting two incrementally new positives to the earnings backdrop.

      Zacks Equity Research

      Healthcare ETF (VHT) Hits New 52-Week High

      by Zacks Equity Research

      Healthcare ETF hits a new 52-week high amid strong earnings and talks of bipartisan deal.

        Swarup Gupta headshot

        Dow 30 Stock Roundup: AmEx, IBM, JNJ, Goldman Beat

        by Swarup Gupta

        The Dow experienced substantial gains over this week, powered primarily by strong earnings expectations and bullish results.

          Zacks Equity Research

          Healthcare ETFs Head to Head: XLV vs. VHT

          by Zacks Equity Research

          Head to head comparison of two Healthcare ETFs, XLV and VHT.

            Zacks Equity Research

            Healthcare ETFs in Focus on Johnson & Johnson Q3 Earnings

            by Zacks Equity Research

            Johnson & Johnson reports Q3 results with both revenues and EPS beating estimates.

              Zacks Equity Research

              Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?

              by Zacks Equity Research

              Though ImmunoGen (IMGN) is progressing with lead ovarian cancer candidate, mirvetuximab soravtansine, the company is likely to face stiff market competition from established products upon approval.

                Zacks Equity Research

                Varian Medical (VAR) Initiates Halcyon Treatment in Europe

                by Zacks Equity Research

                Varian (VAR) has been taking initiatives to gain customers for its broad spectrum of products, especially targeting emerging markets.

                  Sanghamitra Saha headshot

                  Dow ETFs Soar as the Index Hits 23,000

                  by Sanghamitra Saha

                  Dow Jones Industrial Average hits 23,000 and benefits these ETFs.

                    Zacks Equity Research

                    Stock Market News For Oct 18, 2017

                    by Zacks Equity Research

                    Benchmarks finished higher on Tuesday after a slew of strong corporate earnings led gains for healthcare stocks.

                      Zacks Equity Research

                      J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

                      by Zacks Equity Research

                      J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.

                        Zacks Equity Research

                        Market: Spectacular All Around

                        by Zacks Equity Research

                        Market: Spectacular All Around

                          Mark Vickery headshot

                          Q3 Earnings Blasting Off: GS, MS, JNJ and More

                          by Mark Vickery

                          Stronger-than-expected earnings are providing a good tonic for us this morning, even as pre-markets are mixed at this hour.

                            Zacks Equity Research

                            J&J (JNJ) Beats on Q3 Earnings & Sales, Ups 2017 View

                            by Zacks Equity Research

                            Johnson & Johnson (JNJ) beat consensus estimate for both earnings and sales and also raised its 2017 sales and profit outlook.

                              Tracey Ryniec headshot

                              5 Earnings All Stars to Start Off the Week

                              by Tracey Ryniec

                              Nervous about earnings season? This week, it pays to check in with these bellwether stocks.

                                Zacks Equity Research

                                J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use

                                by Zacks Equity Research

                                Johnson & Johnson (JNJ) announced approval of label expansion for its plaque psoriasis drug, Stelara, to include adolescent patients.

                                  Zacks Equity Research

                                  MedTech Players Eyeing Emerging Market Growth Opportunities

                                  by Zacks Equity Research

                                  The gloomy eco-political scenario in the United States and Europe points toward the fact that emerging geographies are playing a crucial role in the growth of the MedTech space globally.

                                    Zacks Equity Research

                                    J&J (JNJ) to Kickstart Pharma Q3 Earnings: What's in Store?

                                    by Zacks Equity Research

                                    J&J's (JNJ) sales and earnings growth are expected to accelerate in third and fourth quarters. The company expects organic sales growth of 4% in the second half of the year.

                                      Zacks Equity Research

                                      Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit

                                      by Zacks Equity Research

                                      Pfizer (PFE) is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin-off, sale or other transaction.

                                        Sweta Killa headshot

                                        Will Dow ETFs Continue to Shine in Q3 Earnings?

                                        by Sweta Killa

                                        The Dow Jones has returned 24.2% since the Election Day compared to a gain of 18.9% for the S&P 500.

                                          Zacks Equity Research

                                          Here's What's Has Happened in the HCV Space Lately

                                          by Zacks Equity Research

                                          A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.

                                            Zacks Equity Research

                                            Johnson & Johnson Files sNDA for Label Expansion of Invokana

                                            by Zacks Equity Research

                                            Johnson & Johnson (JNJ) filed a supplemental New Drug Application to the FDA for the label expansion of Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events in adults with type II diabetes.

                                              Zacks Equity Research

                                              Integra Closes Codman Buyout, Strengthens Neurosurgery Arm

                                              by Zacks Equity Research

                                              With Codman's acquisition by Integra (IART), the neurosurgery business is likely to drive the company's 2018 adjusted earnings per share with a minimum yield of 22 cents.

                                                Arpita Dutt headshot

                                                Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?

                                                by Arpita Dutt

                                                With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.

                                                  Zacks Equity Research

                                                  The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO

                                                  by Zacks Equity Research

                                                  The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO